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Background
Tipranavir/ritonavir (TPV/r) is a potent protease inhibitor
(PI), whose most frequent grade 3/4 toxicity is ALT, AST
and lipids elevations. These alterations seem to be associ-
ated to TPV exposure, being lower with TPV/r 500/100 mg
BID than using TPV/r 500/200 mg BID. Therefore, the tol-
erance of TPV/r could be improved by reducing ritonavir
dose; however, this strategy could be adequate as long as
the virological response is not compromised. In this
regards, therapeutic drug monitoring (TDM) of TPV could
be helpful.
Methods
A prospective study was initiated in HIV antiretroviral-
experienced patients with plasma HIV-RNA <50 copies/
mL under a TPV/r 500/200-based regimen for longer than
24 weeks. Patients were randomized to stay on the same
TPV/r dosing or to switch to TPV/r 500/100 BID. TPV
plasma trough concentrations had to be above the Cmin
(≥20.5 ug/mL) before recruitment in the study. Lipids and
liver enzymes were recorded at baseline and at week 12 of
follow-up. TPV Ctrough was measured using a validated
HPLC-UV.
Summary of results
A total of 10 patients were recruited in the study, five on
TPV/r 500/200 BID and five on TPV/r 500/100 BID. All
were male; mean [range] age, 45 [40–54] years; CD4
count, 550 [390–646] cells/μl; AST, 36 [20–83]; ALT, 29
[16–140]; total cholesterol, 205 [179–261]; triglycerides,
134 [104–384]. While TPV Ctrough at week 12 remained
significantly unchanged in patients on stable TPV/r 500/
200 BID, all patients switched to TPV/r 500/100 BID expe-
rienced a drop in TPV Ctrough ranging from 9 to 30%.
Four out of five patients switched to TPV/r 500/100
showed a decline in AST, ALT and total cholesterol (drop
ranging from 5 to 45%, 15 to 49%, and 2 to 22%, respec-
tively). In contrast, triglycerides only diminished in two
patients (7% and 61%, respectively). In all five patients,
plasma HIV-RNA remained undetectable at week 12.
However, three patients showed sub-therapeutic TPV
Ctrough and accordingly treatment was modified. The
other two patients have maintained undetectable viral
load with similar benefit in lipids and liver enzymes over
12 months of follow-up.
Conclusion
A subset of antiretroviral-experienced patients on success-
ful TPV/r 500/200 BID based regimens could benefit from
ritonavir dose reductions, which may be associated with
improvements in liver enzymes and lipids. However, due
to large inter-individual differences in TPV Ctrough, this
strategy should only be performed using TDM. (Table 1.)
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No data No 24,9 20 27 194 104 ↓ 18% No ↓ 5% ↓ 15% 0% ↑ 123%
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None No 22,8 24 29 205 229 ↓ 9% No ↓ 33% ↓ 35% ↓ 2% ↑ 40%
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